{
    "clinical_study": {
        "@rank": "92251", 
        "arm_group": [
            {
                "arm_group_label": "capsaicin patch", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "placebo patch", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "In the present study the investigators intend to investigate analgesic and sensory effects\n      of a capsaicin patch 8 %(Qutenza) in patients with severe post-herniotomy pain and sensory\n      abnormalities in the skin."
        }, 
        "brief_title": "Capsaicin Patch 8 % for the Treatment of Persistent Pain After Inguinal Herniotomy", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "condition": "Persistent Pain After Inguinal Herniotomy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients ASA (American Society\u00b4s of Anesthesiology\u00b4s classification) scores I-III\n\n          -  Severe post-herniotomy pain for more than six months and with severe pain (numerical\n             rating scale [NRS] 0-10 points) during rest or during movement > 5.\n\n        Exclusion Criteria:\n\n          -  History of an allergic reaction or intolerance to capsaicin or vehicle ingredients in\n             the patches\n\n          -  Severe cardiac impairment, e.g., NYHA (New York Heart Association) Class \u2265 III\n\n          -  Inflamed or injured skin at the application site\n\n          -  Signs of cognitive impairment\n\n          -  Known drug or ethanol abuse"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01699854", 
            "org_study_id": "H-4-2012-055", 
            "secondary_id": "2012-001540-22"
        }, 
        "intervention": [
            {
                "arm_group_label": "capsaicin patch", 
                "intervention_name": "capsaicin patch (qutenza)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "placebo patch", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Capsaicin"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 25, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Copenhagen", 
                    "country": "Denmark", 
                    "state": "Copenhagen \u00d8", 
                    "zip": "2100"
                }, 
                "name": "Rigshospitalet"
            }
        }, 
        "location_countries": {
            "country": "Denmark"
        }, 
        "number_of_arms": "2", 
        "other_outcome": {
            "description": "An interim analysis evaluating pain change (SPID) for capsaicin patch vs. placebo  treatment by an independent statistician following completion of 32 patients.", 
            "measure": "interim analyses", 
            "safety_issue": "No"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "Denmark: Danish Health and Medicines Authority", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Summed pain intensity (SPI) is calculated as median pain intensities at rest, during transition from the supine lying to the standing erect position, and auto-palpation twice each day for the last 3 days at baseline and at 1 months, 2 months and 3 months during follow-up. The primary outcome measure is the maximum difference between the summed pain intensity differences (SPID) for the phases: Baseline, 1 month, 2 month or 3 month. \u0394 SPID is then calculated as the difference in SPID between capsaicin and placebo treated patients.", 
            "measure": "Pain change capsaicin vs. placebo patch treatment", 
            "safety_issue": "No", 
            "time_frame": "Pain intensity assessed at baseline and at 1,2,3 months follow-up"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01699854"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Rigshospitalet, Denmark", 
            "investigator_full_name": "Joakim Bischoff", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Changes in AAS (Activities Assessment Scale) score", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Changes in HADS (Hospital Anxiety and Depression Scale) score", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Changes in QST (Quantitative sensory testing)", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Changes in sleep (Sleep Interference Scale) score", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Changes in S-LANSS (Leeds self-assessment of neuropathic symptoms and signs)", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Changes in intraepidermal nerve fiber density", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Subgroup analysis for pain change(summed pain intensity differences (SPID) capsaicin patch vs. placebo are made for patients with thermal hypoesthesia and thermal normo/hyperesthesia", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Changes in PCS (Pain Catastrophizing Scale) score", 
                "safety_issue": "No"
            }
        ], 
        "source": "Rigshospitalet, Denmark", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Rigshospitalet, Denmark", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014", 
        "why_stopped": "Expiration of the placebo patch"
    }
}